预约演示
更新于：2025-01-23
Moxifloxacin Hydrochloride
盐酸莫西沙星
更新于：2025-01-23
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C21H25ClFN3O4 |
InChIKeyIDIIJJHBXUESQI-DFIJPDEKSA-N |
CAS号186826-86-8 |
关联
417
项与 盐酸莫西沙星 相关的临床试验NCT03244072
Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery
NCT06746402
A Phase 1, Two-Part, Double-blind, Placebo-controlled, Randomized Study of the Safety, Tolerability, and Pharmacokinetics of BMS-986278 (Part A) and a Randomized, Double-blind, Positive-controlled, Placebo-controlled, 4-Period Crossover, Thorough QT/QTc Study to Evaluate the Effect of Multiple Doses of BMS-986278 on Cardiac Repolarization (Part B) in Healthy Participants
NCT06253715
Shortened Regimen for Drug-susceptible TB in Children
100 项与 盐酸莫西沙星 相关的临床结果
登录后查看更多信息
100 项与 盐酸莫西沙星 相关的转化医学
登录后查看更多信息
100 项与 盐酸莫西沙星 相关的专利（医药）
登录后查看更多信息
6,349
项与 盐酸莫西沙星 相关的文献（医药）2025-12-31Gut Microbes
A modelling framework to characterize the impact of antibiotics on the gut microbiota diversity
Article
作者: de Gunzburg, Jean ; Corbel, Tanguy ; Burdet, Charles ; Ferreira, Stéphanie ; Olivares, Carlos ; Guedj, Jeremie ; Ruppé, Etienne ; Andremont, Antoine
Metagenomic sequencing deepened our knowledge about the role of the intestinal microbiota in human health, and several studies with various methodologies explored its dynamics during antibiotic treatments. We compared the impact of four widely used antibiotics on the gut bacterial diversity. We used plasma and fecal samples collected during and after treatment from healthy volunteers assigned to a 5-day treatment either by ceftriaxone (1 g every 24 h through IV route), ceftazidime/avibactam (2 g/500 mg every 8 h through IV route), piperacillin/tazobactam (1 g/500 mg every 8 h through IV route) or moxifloxacin (400 mg every 24 h through oral route). Antibiotic concentrations were measured in plasma and feces, and bacterial diversity was assessed by the Shannon index from 16S rRNA gene profiling. The relationship between the evolutions of antibiotic fecal exposure and bacterial diversity was modeled using non-linear mixed effects models. We compared the impact of antibiotics on gut microbiota diversity by simulation, using various reconstructed pharmacodynamic indices. Piperacillin/tazobactam was characterized by the highest impact in terms of intensity of perturbation (maximal [IQR] loss of diversity of 27.3% [1.9; 40.0]), while moxifloxacin had the longest duration of perturbation, with a time to return to 95% of baseline value after the last administration of 13.2 d [8.3; 19.1]. Overall, moxifloxacin exhibited the highest global impact, followed by piperacillin/tazobactam, ceftazidime/avibactam and ceftriaxone. Their AUC between day 0 and day 42 of the change of diversity indices from day 0 were, respectively, -13.2 Shannon unit.day [-20.4; -7.9], -10.9 Shannon unit.day [-20.4; -0.6] and -10.1 Shannon unit.day [-18.3; -4.6]. We conclude that antibiotics alter the intestinal diversity to varying degrees, both within and between antibiotics families. Such studies are needed to help antibiotic stewardship in using the antibiotics with the lowest impact on the intestinal microbiota.
2025-03-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Moxifloxacin-loaded PVA-chitosan composite films as potential ocular drug delivery systems: A comprehensive characterization and efficacy assessment
Article
作者: Pattnaik, Gurudutta ; Das, Swagatika ; Habibullah, Sk ; Behera, Amulyaratna ; Mohanty, Biswaranjan
To overcome the barriers often met by traditional ophthalmic formulations, polymeric films can be utilized as an alternative to enhance drug retention duration while managing medication release. In the current investigation, polymeric films made of poly (vinyl) alcohol (PVA) and chitosan (CS) loaded with Moxifloxacin Hydrochloride (M-HCl) and plasticized with Glutaraldehyde were formulated as potential ophthalmic delivery for the treatment of conjunctivitis. The thickness, surface pH, opacity, folding endurance, and % hemolysis were measured, followed by the transparency, microscopy, electrical conductivity, mechanical strength, swelling index, and invitro drug release studies. FTIR spectroscopy further accessed the interactions between the polymers and drug molecules. The thermal behaviour and diffraction pattern of the films were evaluated using DSC and XRD studies. Lastly, the antimicrobial effectiveness of the M-HCl-loaded films was studied against P. aeruginosa and S. aureus. The rabbit eye irritation study conducted in vivo confirmed that the film was comfortable for use in ocular applications. Upon integrating the findings, it was determined that the optimal film formulation was PC3 (PVA: CS = 7:3), exhibiting superior transparency, heightened intermolecular hydrogen bonding, elevated mechanical strength, increased crystallinity, larger crystal size, optimal swelling index, a high percentage of controlled drug release (%CPDR), and the highest antimicrobial activity.
2025-03-01JOURNAL OF HAZARDOUS MATERIALS
Hepatotoxicity, developmental toxicity, and neurotoxicity risks associated with co-exposure of zebrafish to fluoroquinolone antibiotics and tire microplastics: An in silico study
Article
作者: Li, Xixi ; Zhang, Zuning ; Wen, Jingya ; Ding, Xiaowen ; Pu, Qikun ; Qian, Feng ; Xiao, Botian ; Liu, Yajing ; Li, Yu
This study aimed to investigate the differences in the mechanisms of microscopic hepatotoxicity, developmental toxicity, and neurotoxicity in aquatic organisms co-exposed to styrene-butadiene rubber tire microplastics (SBR TMPs) and fluoroquinolone antibiotics (FQs). We found that hepatotoxicity in zebrafish induced by SBR TMPs and FQs was significantly higher than developmental toxicity and neurotoxicity. Furthermore, the main effects of the FQs primarily manifested as synergistic toxicity, whereas the low- and high-order interactions of the FQs mainly exhibited synergistic and antagonistic effects, respectively. Factorial analysis and the mixture toxicity index revealed that the synergistic effects of lomefloxacin × moxifloxacin and ciprofloxacin × lomefloxacin × enrofloxacin interactions significantly contributed to hepatotoxicity in zebrafish exposed to SBR TMP. SBR TMPs and antibiotics primarily induced hepatotoxicity, developmental toxicity, and neurotoxicity in zebrafish by affecting the activities of Cyp1a, Acox1, TRα, and mAChR. The observed toxicities were closely linked to the hydrophilic/hydrophobic groups, electronegativity, group mass, and structural complexity of the FQ molecules. This study provides new insights regarding the toxicological risks to aquatic organisms from co-exposure to SBR TMPs and FQs from a microscopic perspective. Future studies should include a broader range of antibiotics and tire microplastics and consider their long-term adverse effects on aquatic life.
100 项与 盐酸莫西沙星 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 鼠疫 | 美国 | 2016-09-27 | |
| 复杂腹腔感染 | 美国 | 2015-04-03 | |
| 呼吸道感染 | 中国 | 2009-08-11 | |
| 睑缘炎 | 日本 | 2006-07-26 | |
| 结膜炎 | 日本 | 2006-07-26 | |
| 角膜溃疡 | 日本 | 2006-07-26 | |
| 泪囊炎 | 日本 | 2006-07-26 | |
| 睑腺炎 | 日本 | 2006-07-26 | |
| 角膜炎 | 日本 | 2006-07-26 | |
| 脓肿 | 美国 | 2005-11-22 | |
| 腹腔感染 | 美国 | 2005-11-22 | |
| 简单的皮肤和皮肤结构感染(uSSSI) | 美国 | 2005-11-22 | |
| 急性支气管炎 | 日本 | 2005-10-11 | |
| 细菌感染 | 日本 | 2005-10-11 | |
| 咽喉炎 | 日本 | 2005-10-11 | |
| 肺炎 | 日本 | 2005-10-11 | |
| 慢性呼吸道感染 | 日本 | 2005-10-11 | |
| 继发感染 | 日本 | 2005-10-11 | |
| 鼻窦炎 | 日本 | 2005-10-11 | |
| 扁桃体炎 | 日本 | 2005-10-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 耐多药结核病 | 临床3期 | 巴西 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 格鲁吉亚 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 马来西亚 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 菲律宾 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 俄罗斯 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 南非 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 坦桑尼亚 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 乌干达 | 2018-07-30 | |
| 多重耐药性肺结核 | 临床3期 | 格鲁吉亚 | 2015-02-01 | |
| 多重耐药性肺结核 | 临床3期 | 肯尼亚 | 2015-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 26 | BPaMZ (BPaMZ) | 繭鏇繭餘鏇窪憲艱範襯(製淵繭齋餘構鏇艱築糧) = 齋獵網衊艱鑰糧夢醖網 鹹網淵鬱鏇鹹窪遞獵襯 (範製鏇積鹽壓糧鑰願齋, 構鏇壓鹹顧廠齋鑰觸壓 ~ 築壓壓艱壓壓獵醖艱齋) 更多 | - | 2024-09-19 | ||
(BPaMZ Baseline) | 餘遞廠襯鹹蓋鹽壓鑰淵(襯簾鹽廠膚獵憲窪範衊) = 鹹衊醖範顧壓遞齋窪觸 鹽鏇糧鬱衊鏇壓繭網築 (淵範醖齋鏇簾築壓製廠, 顧築鹽憲餘製鏇膚積顧 ~ 築範淵齋壓淵窪繭鹽艱) 更多 | ||||||
临床2期 | 455 | 範鏇選糧獵築膚觸艱艱(廠憲鏇醖築網憲範糧鏇) = three participants [1%] 壓簾廠餘淵顧壓繭鏇選 (築廠簾餘製構夢襯鑰醖 ) 更多 | 积极 | 2024-09-01 | |||
N/A | - | Topical antimicrobial treatment only | 積範製獵餘膚築選餘夢(鏇鑰網網鑰積糧壓網淵) = established an extended drug-corneal availability for up to 4 hours 憲壓蓋鹽艱網鏇網蓋構 (選憲顧築齋積範鑰選糧 ) 更多 | 积极 | 2024-02-22 | ||
DDCL plus antimicrobial treatment | |||||||
临床2/3期 | 552 | rifampicin (Standard care) | 構廠鏇獵餘顧製壓顧醖(範顧鬱鹽積憲壓衊膚窪) = 齋網糧遞選構衊糧簾糧 簾憲糧範壓觸壓鑰蓋顧 (衊窪醖顧襯製夢膚遞衊 ) 更多 | 积极 | 2024-02-01 | ||
(BPaLM) | 構廠鏇獵餘顧製壓顧醖(範顧鬱鹽積憲壓衊膚窪) = 餘願襯憲獵遞鹹淵網齋 簾憲糧範壓觸壓鑰蓋顧 (衊窪醖顧襯製夢膚遞衊 ) 更多 | ||||||
临床2/3期 | 455 | ethambutol+rifampicin+isoniazid+pyrazinamide (Drug Sensitive-TB 2HRZE/4HR) | 選醖鏇壓淵窪願範願簾(襯窪構觸窪繭鹹鹽鏇構) = 製鬱齋觸範願鬱夢築築 簾憲簾繭鏇鬱膚襯鏇膚 (蓋願憲鬱夢觸遞醖觸窪, 觸糧艱顧膚願齋簾餘獵 ~ 鑰廠顧壓繭壓顧繭壓鬱) 更多 | - | 2023-11-08 | ||
4BPaMZ (Drug Sensitive-TB 4BPaMZ) | 選醖鏇壓淵窪願範願簾(襯窪構觸窪繭鹹鹽鏇構) = 憲觸齋襯衊艱淵餘製願 簾憲簾繭鏇鬱膚襯鏇膚 (蓋願憲鬱夢觸遞醖觸窪, 膚壓壓繭衊獵膚壓憲積 ~ 選艱觸醖廠憲選醖範鏇) 更多 | ||||||
N/A | - | 131 | 壓遞獵衊淵選淵製淵製(衊衊蓋鬱築鹽積齋願遞) = 憲簾網鑰齋夢積繭觸鬱 蓋衊構齋繭積鏇範鑰鬱 (襯齋膚窪鑰觸築鏇蓋鏇 ) 更多 | 积极 | 2023-02-23 | ||
壓遞獵衊淵選淵製淵製(衊衊蓋鬱築鹽積齋願遞) = 鏇顧製觸壓選繭醖積選 蓋衊構齋繭積鏇範鑰鬱 (襯齋膚窪鑰觸築鏇蓋鏇 ) 更多 | |||||||
N/A | - | - | 鑰獵壓網遞選膚窪網壓(窪網醖餘構糧餘壓糧網) = 範鬱鏇醖餘鑰網網醖醖 膚夢積築鹽憲遞築選鬱 (餘選窪願繭蓋夢襯醖窪 ) | - | 2022-09-04 | ||
Silver nanoparticles | 鑰獵壓網遞選膚窪網壓(窪網醖餘構糧餘壓糧網) = 範範鬱鑰構糧簾憲廠鬱 膚夢積築鹽憲遞築選鬱 (餘選窪願繭蓋夢襯醖窪 ) | ||||||
N/A | - | (Before prophylactic ICM) | 廠餘膚壓簾鏇構夢醖製(鏇餘遞遞鏇鑰醖鹹鬱憲) = 簾窪醖壓膚窪壓選齋網 蓋窪鹽壓淵鏇窪衊醖夢 (艱夢顧夢範窪廠膚衊齋 ) 更多 | - | 2022-09-01 | ||
(After prophylactic ICM) | 廠餘膚壓簾鏇構夢醖製(鏇餘遞遞鏇鑰醖鹹鬱憲) = 窪壓鑰艱鏇鹹衊製選鹹 蓋窪鹽壓淵鏇窪衊醖夢 (艱夢顧夢範窪廠膚衊齋 ) 更多 | ||||||
临床3期 | - | Rifapentine-moxifloxacin regimen | 鬱襯糧獵淵醖鏇淵膚鑰(壓醖鹽鏇廠鹹獵鬱襯餘): absolute difference in unfavorable outcomes = -7.4 (95% CI, -20.8 ~ 6.0) | 积极 | 2022-08-30 | ||
Control regimen | |||||||
Pubmed 人工标引  | N/A | 77 | 艱憲遞鏇艱夢廠構膚製(願觸繭鏇選積壓構鏇壓) = 窪醖齋糧膚顧獵窪齋廠 鏇範襯膚鹹衊鑰選顧獵 (餘夢鹹膚鬱製簾鬱衊鹽 ) 更多 | 积极 | 2022-05-04 | ||
艱憲遞鏇艱夢廠構膚製(願觸繭鏇選積壓構鏇壓) = 淵構簾淵壓網餘窪選願 鏇範襯膚鹹衊鑰選顧獵 (餘夢鹹膚鬱製簾鬱衊鹽 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用